ENTITY
Biogen Inc

Biogen Inc (BIIB US)

142
Analysis
Health CareUnited States
Biogen Inc. develops, manufactures, and commercializes therapies, focusing on neurology, oncology, and immunology. The Company's products address diseases such as multiple sclerosis, non-Hodgkin's lymphoma, rheumatoid arthritis, Crohn's disease, and psoriasis.
more
29 Oct 2018 13:52

Smartkarma’s Week That Was in JP/​​​​KR: Market Turbulence 10 Years After 2008, Coway, & Celltrion

The Korean and Japanese stock markets have fallen sharply in October. Nikkei is down 12% and KOSPI is down 14% in October. It has been 10 years...

Logo
413 Views
Share
22 Oct 2018 22:52

Samsung BioLogics Update

Recent developments in Samsung Biologics Co., (207940 KS)'s business have been mixed with a negative skew. First, partner Merck & Co Inc (MRK...

Share
bullishEisai Co Ltd
03 Jul 2018 20:11

Merck Alliance Provides Stability to Deal With the Outcome of High Risk Alzheimer’s R&D in FY19

We upgrade Eisai Co Ltd (4523 JP) to “Equal-weight” after reviewing our model post FY17 (YE Mar-18) earnings, in light of the augmented peak sales...

30 Jun 2018 07:59

Biogen Exercises Samsung Bioepis Call Option - Summary & Implications

Samsung Biologics Co., Ltd (207940 KS) said in a regulatory filing that Biogen Inc (BIIB US) exercised Bioepis call option. Link of this...

Logo
336 Views
Share
x